A single PSA test at midlife may identify men with a low risk of prostate cancer for up to 20 years, supporting longer screening intervals. Men with a low baseline PSA level at midlife have a low risk ...

New research links PSA and PSA density to long-term prostate cancer risk, supporting risk-adapted screening strategies. Learn more about the 20-year findings.

PSA density is strongly associated with pathological stage and biochemical-free survival after radical prostatectomy for prostate cancer, researchers conclude. In lower grade prostate cancers (biopsy ...

In a population-based cohort study, a single prostate-specific antigen (PSA) measurement in men aged 45-70 years effectively identified individuals with low risk for cancer. Men with PSA levels < 1.00 ...

Automated prostate lesion detection and PI-RADS assessment with deep learning. The relative contributions of the Genomic Prostate Score and comorbidity profile in predicting outcomes in surgically ...

The clinical outcome of second generation anti-hormonal therapy in patients with metastatic castrate-resistant prostate cancer following CHAARTED regimen. This is an ASCO Meeting Abstract from the ...

To compare PSAD with another PSA-related parameter, the PERCENT FREE PSA (%fPSA), for the detection of prostate cancer, and to define possible cut-off values for PSAD. The authors conclude that PSAD ...

In the wake of more than a decade of controversy over PSA testing, research is emerging that points to new approaches for the stratification of prostate cancer risk. Two noninvasive tests — an ...

September is Prostate Cancer Awareness Month. The COVID-19 pandemic continues to lead to unacceptable morbidity and mortality rates in the Bahamas. Approximately 100 men die every year in the Bahamas ...

Prostate specific antigen (PSA) is a type of protein released by the prostate gland. Screening for possible prostate cancer involves taking a PSA blood test, which is recommended annually starting at ...